Qian Niu,Jiamin Liu,Xiaoxiao Luo,Beibei Su,Xianglin Yuan. Future of targeted therapy for gastrointestinal cancer: Claudin 18.2. Oncol Transl Med, 2021, 7: 102-107.
Future of targeted therapy for gastrointestinal cancer: Claudin 18.2
Received:November 16, 2020  Revised:June 22, 2021
View Full Text  View/Add Comment  Download reader
KeyWord:gastrointestinal cancer; claudin 18.2 (CLDN18.2); targeted therapy; ideal monoclonal antibody 362 (IMAB362); chimeric antigen receptor (CAR) T cells treatment
Author NameAffiliationE-mail
Qian Niu Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 645020547@qq.com 
Jiamin Liu Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Xiaoxiao Luo Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Beibei Su Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Xianglin Yuan Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology xlyuan1020@163.com 
Hits: 1576
Download times: 1907
Abstract:
      The treatment of gastrointestinal cancer has always been a crucial research area, and targeted therapy has been receiving increasing attention. At present, the effect of targeted therapy is unsatisfactory for gastric cancer. Thus, the discovery of new targets is crucial. Claudin 18.2 (CLDN18.2), a member of the claudin family, belongs to the tight junction protein family that controls the flow of molecules between cell layers. CLDN18.2 expression has been discussed in many studies. In recent years, there have been many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362. Furthermore, CLDN18.2- specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors, such as gastric and pancreatic cancers. Considerable research has been focused on CLDN18.2. CLDN18.2, a newly discovered marker for precise targeted therapy of gastric cancer, could offer new hope for the treatment of gastric cancer.
Close